Patents by Inventor Eliot MORRISON

Eliot MORRISON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOUBLE-STRANDED RNAI AGENTS AND COMPOSITIONS FOR REDUCING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND METHODS OF USE THEREOF
    Publication number: 20260092279
    Abstract: There are disclosed certain double-stranded RNA (dsRNA) or siRNA agents for inhibition of angiopoietin-like 3 gene expression, compositions that include angiopoietin-like 3 agents and methods of use thereof. The double-stranded RNA (dsRNA) or siRNA agents are particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions as well as in the treatment of heart failure and chronic kidney disease.
    Type: Application
    Filed: September 29, 2025
    Publication date: April 2, 2026
    Inventors: Ariana FOINQUINOS, Eva HURT-CAMEJO, Xiao-Rong PENG, Eliot MORRISON, Stavros GIANNAKOPOULOS, Sibylle DAMES, Timo JOHANNSSEN, Lucas BETHGE, Steffen SCHUBERT, Marie WIKSTRÖM LINDHOLM
  • Nucleic acids for inhibiting expression of MASP-2 in a cell
    Publication number: 20250230441
    Abstract: The invention relates to double-stranded nucleic acid molecules that interfere with or inhibit mannan-binding lectin serine protease 2 (MASP-2) gene expression. It further relates to therapeutic uses of such inhibition such as for the treatment of diseases and disorders associated with complement pathway deregulation, particularly of the Lectin pathway, and/or with over-activation or with ectopic expression or localisation or accumulation, of MASP-2 in the body.
    Type: Application
    Filed: February 10, 2023
    Publication date: July 17, 2025
    Inventors: Eliot Morrison, Sibylle Dames, Maciej Czajkowski, Verena Aumiller, Timo Johannssen
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF COMPLEMENT FACTOR B (CFB) IN A CELL
    Publication number: 20250136977
    Abstract: The invention relates to nucleic acid products that interfere with complement factor B (CFB) gene expression or inhibit its expression. The nucleic acids are preferably for use in the prophylaxis or treatment of complement associated diseases, disorders or syndromes, particularly C3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), lupus nephritis, IgA nephropathy (IgA N), myasthenia gravis (MG), and primary membranous nephropathy.
    Type: Application
    Filed: September 1, 2022
    Publication date: May 1, 2025
    Inventors: Sibylle Dames, Eliot Morrison, Verena Aurniller, Timo Johannssen, Stefan Rathjen, Steffen Schubert
  • Nucleic acids for inhibiting expression of PROS1 in a cell
    Patent number: 11820971
    Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.
    Type: Grant
    Filed: July 25, 2022
    Date of Patent: November 21, 2023
    Assignees: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBH
    Inventors: Ute Schaeper, Sibylle Dames, Eliot Morrison, Raja Prince Eladnani, Anne Angelillo-Scherrer
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL
    Publication number: 20230019513
    Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.
    Type: Application
    Filed: July 25, 2022
    Publication date: January 19, 2023
    Applicants: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBH
    Inventors: Ute SCHAEPER, Sibylle DAMES, Eliot MORRISON, Raja PRINCE ELADNANI, Anne ANGELILLO-SCHERRER
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL
    Publication number: 20220135974
    Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.
    Type: Application
    Filed: November 11, 2021
    Publication date: May 5, 2022
    Applicants: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBH
    Inventors: Ute SCHAEPER, Sibylle DAMES, Eliot MORRISON, Raja PRINCE ELADNANI, Anne ANGELILLO-SCHERRER